• 1
    Sachar DB. Defining clinical activity in Crohn's disease In: Hanauer SB, Jewell DP, Rachmilewitz D, Scholmerich J, eds. Inflammatory Bowel Disease. Dordrecht: Kluwer Academic Publishers, 2002: 329.
  • 2
    Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 3
    Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979; 77: 82942.
  • 4
    De Dombal FT, Softley A. IOIBD report no. 1: Observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut 1987; 28: 47481.
  • 5
    Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514.
  • 6
    Myren J, Bouchier IA, Watkinson G, et al. Multinational Inflammatory Bowel Disease Survey 1976--82. A further report on 2,657 cases. Scand J Gastroenterol Suppl 1984; 95: 127.
  • 7
    Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity—the Cape Town index. S Afr Med J 1985; 68: 5023.
  • 8
    Van Hees PA, Van Elteren PH, Van Lier HJ, Van Tongeren JH. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 27986.
  • 9
    Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 2732.
  • 10
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 11
    Drossman DA, Leserman J, Li ZM, Mitchell CM, Zagami EA, Patrick DL. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 70112.
  • 12
    Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 80410.
  • 13
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106: 28796.
  • 14
    Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 91(6): 14904.
  • 15
    Boirivant M, Leoni M, Taricotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn's disease. J Clin Gastroenterol 1988; 10: 4015.
  • 16
    Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119(1): 1522.
  • 17
    Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroentrol 2002; 97(8): 18678.
    Direct Link:
  • 18
    Sturniolo GC, Di Leo V, Ferronato A, D'Odorico A, D'Inca R. Zinc supplementation tightens ‘leaky gut’ in Crohn's disease. Inflamm Bowel Dis 2001; 7(2): 948.
  • 19
    Arnott IDR, Drummond H, Gosh S. Gut mucosal secretion of interleukin 1β and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig Dis Sci 2001; 46: 4029.
  • 20
    D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999; 94(10): 295660.
  • 21
    Waye JD. The role of colonoscopy in the differential diagnosis of inflammatory bowel disease. Gastrointest Endosc 1977; 23(3): 1504.
  • 22
    Modigliani R, Mary JY presenting the GETAID. Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci 1987; 32(12): 13709.
  • 23
    Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30(7): 9839.
  • 24
    Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98(4): 8118.
  • 25
    Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102(5): 164753.
  • 26
    Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35(2): 2315.
  • 27
    D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116(5): 102934.
  • 28
    Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31(3): 3258.
  • 29
    D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112(5): 147581.
  • 30
    D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999; 50(5): 66771.
  • 31
    Colombel JF, Rutgeerts P, Yan S, et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn's disease patients. Gastroenterology 2002; 122: A613(Abstract).
  • 32
    D'Haens G, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002; 122: A100 (Abstract).
  • 33
    Daperno M, Van Assche G, Bulois P, et al. Development of Crohn's disease endoscopic score (CDES): a simple index to assess endoscopic severity of Crohn's disease. Gastroenterology 2002; 122: A216(Abstract).
  • 34
    Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 66572.
  • 35
    Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Koremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99(4): 95663.